HOME >> BIOLOGY >> NEWS
ChemGenex uses genomics approach to develop new anticancer drug, predict possible side effects

Gene expression changes in response to drugs in cell culture and living systems provide unique insights for their development and use

MENLO PARK, CA (October 30, 2001): Most genomics research is currently aimed at identifying and validating new gene targets for use in early stage drug discovery. However, genomics can also play a key role now in preclinical and clinical drug development, including predicting potential drug toxicities and helping developers design clinical trials, say scientists from ChemGenex Therapeutics. They discussed data today illustrating the use of chemical genomics approaches in evaluating the potential of their investigational drug called Ceflatonin against leukemias and human solid tumors. The researchers presented their findings at the American Association of Cancer Research National Cancer Institute European Organization for Research and Treatment of Cancer conference on Molecular Targets and Cancer Therapeutics taking place from October 29 to November 3 in Orlando, Florida.

Understanding how genes perform in response to chemicals in cell cultures, as well as in diseased and normal tissues in living systems can help researchers identify and evaluate potential new drugs more efficiently than ever before, said Dennis Brown, Ph.D., chairman, chief executive officer and founder of ChemGenex Therapeutics, Inc.

Such knowledge can help spotlight possible drug toxicities, as well as identify which patients may best benefit from treatment with a specific drug, he continued. In addition, chemical genomics can aid in the design of efficient clinical trials by helping trial designers predict the most effective doses and dose scheduling, as well as provide key insights into drug bioavailability, distribution and metabolism. Using genomics in this way to help patients receive most effectively those medicines that will be most useful to them is a major goal of the genomics revolution.

Based on its chem
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
30-Oct-2001


Page: 1 2 3

Related biology news :

1. International symposium on nutritional genomics
2. APS announces the winners of its 2004 postdoctoral fellowship in physiological genomics
3. Full promise of genomics in disease research yet to be realized
4. Pharmacogenomics could replace trial-and-error with science from the human genome
5. Dartmouth Medical School awarded $9 million grant for genomics research
6. Functional genomics enables easy target identification and drives drug discovery
7. Library on a Slide: Whole genome microarrays for comparative genomics
8. New genomics tool boosts diabetes research
9. Bacteriophage genomics approach to antimicrobial drug discovery published in Nature Biotechnology
10. Emerging frontiers genomics grant for blue-green bacteria
11. What can the genomics revolution teach us about global change?

Post Your Comments:
(Date:2/5/2015)... 28, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... Global Online CEO Conference on January 29 th ... Pereira , CEO of NXT-ID will present and host ... Wocket smart wallet and its full suite of biometric ...
(Date:2/5/2015)... , Jan. 30, 2015  It is gratifying ... power and potential for genomic science as a means ... disease prevention and treatment.  I was honored to participate ... government-funded precision medicine program. Since the ... science of genomics—from the first sequenced genome of a ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the ... report to their offering. , The ... individual is who she/he is claiming to be, and for ... unique physical characteristics, such as fingerprint, hand or palm print, ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
(Date:3/3/2015)... Experts and industry insiders from around the ... Alltech REBELation exploring innovation, inspiration and world-changing ideas in ... 31st year, Alltech’s annual international conference traditionally draws more ... to join the REBELation at an extra discount registration ... at which point the standard early registration rate will ...
(Date:3/3/2015)... 2015 /CNW/- SQI Diagnostics Inc. (TSX:V: SQD), a life sciences ... products for advanced microarray diagnostics, today announced it ... its Management team. In his capacity as CFO ... from a development stage to a commercially successful ... Company,s capital market strategy and to secure funding ...
(Date:3/3/2015)... 3, 2015  Regenicin, Inc. (OTC Bulletin Board: ... development of and commercialization of regenerative cell therapies to ... today that it has received the final payment to ... Inc. (OTC Bulletin Board: AMBS ). ... the final payments due to Regenicin in the amount ...
(Date:3/3/2015)... ROCKVILLE, Md. , March 3, 2015  RegeneRx ... an editorial in the scientific journal, Expert Opinion ... and his colleague, Dr. Zhenggang Zhang , at ... reported that Thymosin beta 4 (TB4) has ... (PNS) remodeling 24 hours or more post-injury, leading to ...
Breaking Biology Technology:World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
Cached News: